Published in J Infect Dis on September 15, 2004
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog (2007) 2.33
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology (2006) 1.45
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol (2006) 1.29
The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr (2010) 1.22
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS (2014) 1.05
HIV latency: present knowledge, future directions. Future Virol (2006) 1.04
Chromatin, gene silencing and HIV latency. Genome Biol (2007) 1.01
Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses (2011) 0.99
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother (2014) 0.99
Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology (2005) 0.96
Histone deacetylases in viral infections. Clin Epigenetics (2010) 0.93
Latency reversal and viral clearance to cure HIV-1. Science (2016) 0.92
Molecular Understanding of HIV-1 Latency. Adv Virol (2012) 0.90
Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. J Virol (2005) 0.87
Genome-wide analysis of histone modifications in latently HIV-1 infected T cells. AIDS (2014) 0.84
Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PLoS One (2012) 0.81
Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy. Antimicrob Agents Chemother (2015) 0.80
Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir. HIV Clin Trials (2012) 0.79
Animal models in HIV cure research. J Virus Erad (2015) 0.76
New Drugs in the Pipeline for the Treatment of HIV: a Review. Curr Infect Dis Rep (2017) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
The challenge of finding a cure for HIV infection. Science (2009) 8.41
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 6.99
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity (2003) 6.19
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med (2009) 5.47
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol (2007) 3.71
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol (2004) 3.56
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol (2006) 3.37
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis (2004) 3.23
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
A population-based study of primary human herpesvirus 6 infection. N Engl J Med (2005) 3.07
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis (2004) 3.01
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Defining the sequence-recognition profile of DNA-binding molecules. Proc Natl Acad Sci U S A (2006) 2.97
Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol (2005) 2.89
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol (2005) 2.87
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Immune activation and AIDS pathogenesis. AIDS (2008) 2.85
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis (2008) 2.77
Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics (2003) 2.76
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol (2003) 2.69
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis (2010) 2.45
Genital herpes complicating pregnancy. Obstet Gynecol (2005) 2.45
Understanding the benign nature of SIV infection in natural hosts. J Clin Invest (2007) 2.43
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood (2003) 2.41
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2003) 2.40
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer (2010) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med (2014) 2.36
The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med (2005) 2.34
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis (2008) 2.31
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol (2007) 2.18
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Dual HIV-1 infection associated with rapid disease progression. Lancet (2004) 2.17
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11